A BILL 
To amend the Federal Food, Drug, and Cosmetic Act to 
establish a time-limited conditional approval pathway, 
subject to specific obligations, for certain drugs, and 
for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Conditional Approval 
4
Act’’. 
5
19:13 Dec 21, 2019
H5497
2 
•HR 5497 IH
SEC. 2. CONDITIONAL APPROVAL OF NEW HUMAN DRUGS. 
1
(a) IN GENERAL.—Subchapter A of chapter V of the 
2
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 351 
3
et seq.) is amended by adding at the end the following: 
4
‘‘SEC. 524B. CONDITIONAL AND TIME-LIMITED APPROVAL 
5
PATHWAY FOR NEW DRUGS. 
6
‘‘(a) PATHWAY
REQUIREMENTS.—The Secretary 
7
shall, at the request of the sponsor of a new drug, grant 
8
provisional and time-limited approval of such drug under 
9
this section, if the Secretary determines— 
10
‘‘(1) it is likely that the sponsor will be able to 
11
provide comprehensive clinical data after such drug 
12
is conditionally approved; 
13
‘‘(2) such drug is intended for the treatment, 
14
prevention, or medical diagnosis of a seriously debili-
15
tating disease, a life-threatening disease, or a chron-
16
ic condition; 
17
‘‘(3) the expected benefits of the drug outweigh 
18
the potential risks to patients, taking into account 
19
the fact that additional data are still required to as-
20
sess the drug and the severity of the underlying dis-
21
ease or condition the drug is intended to treat; 
22
‘‘(4) there are no existing meaningful treat-
23
ments for the disease or condition that the drug is 
24
intended to treat; 
25
22:47 Dec 23, 2019
H5497
3 
•HR 5497 IH
‘‘(5) confirmatory clinical trials are difficult or 
1
costly to conduct; and 
2
‘‘(6) such drug is intended to treat a disease or 
3
condition for which no more than 2 meaningful 
4
treatments currently exist. 
5
‘‘(b) APPROVAL REQUIREMENTS.— 
6
‘‘(1) IN GENERAL.—Not later than 180 days 
7
after the date on which the Secretary receives a re-
8
quest for conditional approval under subsection (a) 
9
with respect to a new drug, the Secretary shall re-
10
quire the sponsor of such drug to— 
11
‘‘(A) complete in a timely manner clinical 
12
investigations to provide full demonstration of 
13
safety and effectiveness as described under sec-
14
tion 505 of the Federal Food, Drug, and Cos-
15
metic Act or section 351 of the Public Health 
16
Service Act, as applicable; 
17
‘‘(B) conduct clinical trials other than con-
18
firmatory trials, to demonstrate a certain de-
19
gree of safety and efficacy of the drug; and 
20
‘‘(C) demonstrate that necessary post-mar-
21
ket surveillance and risk-management tools are 
22
in place with respect to the drug. 
23
‘‘(2) PERIOD
OF
CONDITIONAL
APPROVAL.— 
24
The period of conditional approval for a drug under 
25
19:13 Dec 21, 2019
H5497
4 
•HR 5497 IH
this section is effective for a 1-year period and is 
1
thereafter renewable by the Secretary annually for 
2
up to 4 additional 1-year terms. A conditional ap-
3
proval shall be in effect for no more than 5 years 
4
from the date of approval under this section. 
5
‘‘(3) TIME
LIMITATION.—If any conditionally 
6
drug approved under this section is not brought to 
7
market within 3 years of the conditional approval, 
8
any conditional approval granted under this section 
9
with respect to such drug shall be deemed invalid. 
10
‘‘(4) REQUIREMENTS.—As a condition on re-
11
ceipt of conditional approval under this section, the 
12
Secretary shall require the sponsor of the drug to 
13
agree to the following: 
14
‘‘(A) Complete in a timely manner such 
15
clinical investigations to provide a full dem-
16
onstration of effectiveness as the Secretary de-
17
termines to be necessary for approval of the 
18
drug under section 505 of this Act or section 
19
351 of the Public Health Service Act, as appli-
20
cable. 
21
‘‘(B) Submit to the Secretary an annual 
22
report on the progress of the sponsor in con-
23
ducting the clinical investigations required 
24
under this section. 
25
19:13 Dec 21, 2019
H5497
5 
•HR 5497 IH
‘‘(C) Ensure that all labeling and pro-
1
motional materials for the drug bear the state-
2
ment ‘conditionally approved by the FDA pend-
3
ing a full demonstration of effectiveness under 
4
applicable lll’ (specifying the application 
5
number assigned by the Secretary in place of 
6
the blank). 
7
‘‘(5) APPLYING
FOR
FULL
APPROVAL.—The 
8
sponsor of a drug granted conditional approval pur-
9
suant to this section may, at any point, submit an 
10
application for full approval as described under sec-
11
tion 505 of the Federal Food, Drug, and Cosmetic 
12
Act or section 351 of the Public Health Service Act, 
13
as applicable. 
14
‘‘(6) UTILIZATION OF REAL WORLD EVIDENCE 
15
TO SUPPORT FULL APPROVAL.—The Secretary shall 
16
allow the use of real world evidence, as defined in 
17
section 505F(b), and collected by the sponsor of a 
18
drug during the duration of conditional approval 
19
granted approval to this subsection, to supplement 
20
an application for full approval, in addition to other 
21
post-approval studies. 
22
‘‘(c) LIMITATION ON LIABILITY.— 
23
‘‘(1) IN GENERAL.—With respect to any claim 
24
under State law alleging that a drug sold or other-
25
19:13 Dec 21, 2019
H5497
6 
•HR 5497 IH
wise made available pursuant to a grant of condi-
1
tional approval under this section is unsafe or inef-
2
fective, no liability in a cause of action shall lie 
3
against a sponsor or manufacturer, unless the rel-
4
evant conduct constitutes reckless or willful mis-
5
conduct, gross negligence, or an intention tort under 
6
any applicable State law. 
7
‘‘(2) RULE OF CONSTRUCTION.—Except as set 
8
forth in subparagraph (A), nothing in this sub-
9
section shall be construed to modify or otherwise af-
10
fect the right of any person to bring private action 
11
under any Federal or State product liability, tort, 
12
consumer protection, or warranty law. 
13
‘‘(d) DEFINITIONS.—In this Act: 
14
‘‘(1) SERIOUSLY
DEBILITATING
DISEASES.— 
15
The term ‘severely debilitating diseases’ means dis-
16
eases or conditions that cause major irreversible 
17
morbidity. 
18
‘‘(2) LIFE-THREATENING DISEASES.—The term 
19
‘life-threatening diseases’ means— 
20
‘‘(A) a disease or condition where the like-
21
lihood of death is high unless the course of the 
22
disease is interrupted; or 
23
19:13 Dec 21, 2019
H5497
7 
•HR 5497 IH
‘‘(B) a disease or condition with potentially 
1
fatal outcomes, where the end point of clinical 
2
trial analysis is survival. 
3
‘‘(3) CHRONIC CONDITION.—The term ‘chronic 
4
condition’ means a disease or condition that— 
5
‘‘(A) usually lasts for 3 months or longer; 
6
and 
7
‘‘(B)(i) requires ongoing medical attention; 
8
or 
9
‘‘(ii) limits activities of daily living.’’. 
10
(b) REGULATIONS AND GUIDANCE.—Not later than 
11
1 year after the date of the enactment of this Act, the 
12
Secretary of Health and Human Services shall issue final 
13
regulations and guidance for carrying out section 524B 
14
of the Federal Food, Drug, and Cosmetic Act. 
15
(c) CONFORMING AMENDMENT.—Section 505(a) of 
16
the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
17
355(a)) is amended by inserting ‘‘, or there is in effect 
18
a conditional approval under section 524B with respect 
19
to such drug’’ before the period. 
20
Æ 
19:13 Dec 21, 2019
H5497
